Atezolizumab / hyaluronidase
Class
Targeted therapy
Subclass
Anti-PD-L1 monoclonal antibody / recombinant human hyaluronidase combination
Substance name
Atezolizumab / hyaluronidase, atezolizumab / hyaluronidase-tqjs
Brand names
Tecentriq Hybreza®
Contains
Atezolizumab
Hyaluronidase (recombinant)
Common formulations
Solution for injection
Dosage and administration
Adults patients
Alveolar soft part sarcoma • Unresectable or metastatic
HCC • Unresectable or metastatic, not treated with systemic therapy
Melanoma in patients with BRAF V600 mutation • Unresectable or metastatic
Non-small cell lung cancer • Stage II-IIIA, PD-L1 expression on ≥ 1% of tumor cells, adjuvant setting
Non-small cell lung cancer • Metastatic, progressing during or after platinum-based chemotherapy
Non-small cell lung cancer without EGFR mutation, ALK rearrangement • Metastatic, PD-L1 expression on ≥ 50% of tumor cells or PD-L1 stained tumor-infiltrating immune cells covering ≥ 10% of the tumor area
Non-small cell lung cancer without EGFR mutation, ALK rearrangement • Non-squamous, metastatic
Small cell lung cancer • Extensive-stage
Indications for use
Labeled indications
Adults
Safety risks
Contraindications
Hypersensitivity to atezolizumab/hyaluronidase or its components
Warnings and precautions
GvHD, hepatic veno-occlusive disease
Immune-mediated adverse reactions
Infusion-related reactions
Specific populations
Renal impairment
eGFR ≥ 30 mL/min/1.73 m²
eGFR < 30 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource